<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783094</url>
  </required_header>
  <id_info>
    <org_study_id>12757</org_study_id>
    <secondary_id>H6D-JE-LVIA</secondary_id>
    <nct_id>NCT00783094</nct_id>
  </id_info>
  <brief_title>Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks Followed by an Open-Label Extension to Evaluate the Long-Term Safety and Efficacy of Tadalafil in Japanese Men With Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the
      efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an
      open-label extension to evaluate the long-term safety and efficacy of tadalafil in Japanese
      men with signs and symptoms of benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events During 12 Weeks of the Study</measure>
    <time_frame>Baseline through 12 weeks</time_frame>
    <description>A listing of Adverse Events are reported in the Reported Adverse Event Section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Heart Rate at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Measurement of nanograms of PSA per milliliter (ng/mL) of blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment</measure>
    <time_frame>End of 12 weeks of double-blind through 54 weeks</time_frame>
    <description>A listing of Adverse Events are reported in the Reported Adverse Event Section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure During at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Heart Rate at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>Measurement of nanograms of PSA per milliliter (ng/mL) of blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint</measure>
    <time_frame>Baseline, 54 weeks</time_frame>
    <description>Post residual volume (PVR) is measured by ultrasound at regular intervals.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tadalafil 2.5 milligrams (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 2.5 mg</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Tadalafil 2.5 milligrams (mg)</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 5 mg</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Tadalafil 5 mg</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese Males, 45 years old or older, with benign prostatic hyperplasia (BPH) for at
             least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS)
             greater than or equal to 13 at Visit 2.

          -  Agree not to use any other approved or experimental pharmacologic BPH, erectile
             dysfunction (ED), and/or overactive bladder (OAB) treatments at any time during the
             study.

          -  Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any
             other BPH therapy, ED or OAB therapy for specified duration of time prior to Visit 2.

        Exclusion Criteria:

          -  Prostate specific antigen (PSA) score beyond acceptable range defined for study at
             Visit 1.

          -  History of urinary retention or lower urinary tract (bladder) stones within 6 months
             of Visit 1.

          -  History of urethral obstruction due to stricture, valves, sclerosis, or tumor at Visit
             1.

          -  Clinical evidence of prostate cancer at Visit 1.

          -  Clinical evidence of any of the bladder or urinary tract conditions, which may affect
             lower urinary tract symptom at Visit 1.

          -  History of cardiac conditions, including Angina requiring certain treatment with
             nitrates, unstable angina defined for study, positive cardiac stress test before
             starting the study.

          -  History of significant central nervous system (CNS) injuries (including stroke or
             spinal cord injury) within 6 months of Visit 1.

          -  Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens,
             luteinizing hormone-releasing hormone (LHRH) agonists/antagonists, or anabolic
             steroids at Visit 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>274-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>226-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>607-8085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>561-0832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>150-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>June 25, 2010</results_first_submitted>
  <results_first_submitted_qc>June 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2010</results_first_posted>
  <last_update_submitted>March 18, 2011</last_update_submitted>
  <last_update_submitted_qc>March 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil 2.5 mg</title>
          <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tadalafil 5 mg</title>
          <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Double-Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil 2.5 mg</title>
          <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tadalafil 5 mg</title>
          <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="140"/>
            <count group_id="B4" value="422"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="7.4"/>
                    <measurement group_id="B2" value="66.9" spread="7.7"/>
                    <measurement group_id="B3" value="67.0" spread="6.9"/>
                    <measurement group_id="B4" value="66.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline (Visit 3) Benign Prostatic Hyperplasia Severity</title>
          <description>Participants with BPH were defined as having had signs and symptoms of benign prostatic hyperplasia (BPH) (as diagnosed by a qualified physician) &gt;6 months at Visit 1. Signs and symptoms of BPH included those associated with voiding (obstructive symptoms, such as incomplete emptying, intermittency, weak stream, straining)and/or storage (irritative symptoms, such as frequency, urgency, or nocturia).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Alcohol Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Tobacco Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Recorded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Alpha-blocker Use</title>
          <description>Actual use of alpha-blockers within the previous 12 months.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Benign Prostatic Hyperplasia Therapy</title>
          <description>Actual benign prostatic hyperplasia (BPH) therapy within the previous 12 months.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Overactive Bladder Therapy</title>
          <description>Actual overactive bladder (OAB) therapy within the previous 12 months.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" spread="2.4"/>
                    <measurement group_id="B2" value="23.5" spread="2.6"/>
                    <measurement group_id="B3" value="23.6" spread="2.9"/>
                    <measurement group_id="B4" value="23.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of BPH</title>
          <description>Participants had signs and symptoms of benign prostatic hyperplasia (BPH) (as diagnosed by a qualified physician) &gt;6 months at Visit 1.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="3.0"/>
                    <measurement group_id="B2" value="4.5" spread="3.3"/>
                    <measurement group_id="B3" value="4.1" spread="2.9"/>
                    <measurement group_id="B4" value="4.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.0" spread="5.9"/>
                    <measurement group_id="B2" value="166.9" spread="6.1"/>
                    <measurement group_id="B3" value="166.3" spread="6.3"/>
                    <measurement group_id="B4" value="166.4" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Postvoid Residual Volume</title>
          <description>Postvoid residual volume (PVR) was measured by ultrasound at regular intervals.</description>
          <units>mililiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="46.6"/>
                    <measurement group_id="B2" value="32.2" spread="36.4"/>
                    <measurement group_id="B3" value="31.6" spread="42.7"/>
                    <measurement group_id="B4" value="33.0" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="8.6"/>
                    <measurement group_id="B2" value="65.4" spread="8.3"/>
                    <measurement group_id="B3" value="65.4" spread="10.2"/>
                    <measurement group_id="B4" value="65.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint</title>
        <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint</title>
          <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
          <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.4"/>
                    <measurement group_id="O2" value="-4.9" spread="0.4"/>
                    <measurement group_id="O3" value="-3.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, prior alpha blocker use (yes/no), and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, prior alpha blocker use (yes/no) and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 5 mg - Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint</title>
        <description>IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint</title>
          <description>IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
          <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="0.2"/>
                    <measurement group_id="O2" value="-1.6" spread="0.2"/>
                    <measurement group_id="O3" value="-1.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, prior alpha blocker use (yes/no) and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.487</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, prior alpha blocker use (yes/no) and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 5 mg - Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint</title>
        <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint</title>
          <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
          <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.3"/>
                    <measurement group_id="O2" value="-3.3" spread="0.3"/>
                    <measurement group_id="O3" value="-2.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.228</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, prior alpha blocker use (yes/no) and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, prior alpha blocker use (yes/no) and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 5 mg - Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint</title>
        <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint</title>
          <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
          <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.1"/>
                    <measurement group_id="O2" value="-0.7" spread="0.1"/>
                    <measurement group_id="O3" value="-0.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment,BPH severity (moderate/severe), prior alpha blocker use (yes/no), and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment,BPH severity (moderate/severe), prior alpha blocker use (yes/no) and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 5 mg - Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint</title>
        <description>The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint</title>
          <description>The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.</description>
          <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.1"/>
                    <measurement group_id="O2" value="-0.8" spread="0.1"/>
                    <measurement group_id="O3" value="-0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.904</p_value>
            <method>ANCOVA</method>
            <method_desc>with effects for treatment,BPH severity (moderate/severe), prior alpha blocker use (yes/no), and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.800</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, BPH severity(moderate/severe), prior alpha blocker use (yes/no), and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint</title>
        <description>Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint</title>
          <description>Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).</description>
          <population>Participants in the Full Analysis Set (FAS): participants who were randomized and started study medication.</population>
          <units>milliliters per second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.3"/>
                    <measurement group_id="O2" value="0.6" spread="0.3"/>
                    <measurement group_id="O3" value="1.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, BPH severity (moderate/severe), prior alpha blocker use (yes/no), and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>ANCOVA</method>
            <method_desc>With effects for treatment, BPH severity (moderate/severe), prior alpha blocker use (yes/no), and baseline value.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Tadalafil 5 mg - Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement</title>
        <description>Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Participants who received 2.5 mg or 5 mg tadalafil once daily during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement</title>
          <description>Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.</description>
          <population>Participants who received 2.5 mg or 5 mg tadalafil once daily during the double-blind period.</population>
          <units>nanogram/milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-6 hours (n=225, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" spread="44.0"/>
                    <measurement group_id="O2" value="169" spread="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-12 hours (n=72, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" spread="37.6"/>
                    <measurement group_id="O2" value="140" spread="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-24 hours (n=102, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="49.1"/>
                    <measurement group_id="O2" value="93.6" spread="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-48 hours (n=11, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="89.7"/>
                    <measurement group_id="O2" value="75.2" spread="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events During 12 Weeks of the Study</title>
        <description>A listing of Adverse Events are reported in the Reported Adverse Event Section.</description>
        <time_frame>Baseline through 12 weeks</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events During 12 Weeks of the Study</title>
          <description>A listing of Adverse Events are reported in the Reported Adverse Event Section.</description>
          <population>All randomized participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure at 12-Week Endpoint</title>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Safety Analysis Set: all randomized participants who received study treatment grouped by the treatment actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at 12-Week Endpoint</title>
          <population>Safety Analysis Set: all randomized participants who received study treatment grouped by the treatment actually taken.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="11.9"/>
                    <measurement group_id="O2" value="-3.4" spread="12.2"/>
                    <measurement group_id="O3" value="-0.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="9.5"/>
                    <measurement group_id="O2" value="-2.9" spread="8.3"/>
                    <measurement group_id="O3" value="-0.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <p_value_desc>P-Value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <p_value_desc>P-Value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxin rank sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.705</p_value>
            <p_value_desc>P-Value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.173</p_value>
            <p_value_desc>P-Value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Heart Rate at 12-Week Endpoint</title>
        <time_frame>Baseline, 12 Weeks</time_frame>
        <population>Safety Analysis Set: all randomized participants who received study treatment grouped by the treatment actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Heart Rate at 12-Week Endpoint</title>
          <population>Safety Analysis Set: all randomized participants who received study treatment grouped by the treatment actually taken.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="9.9"/>
                    <measurement group_id="O2" value="-1.2" spread="9.8"/>
                    <measurement group_id="O3" value="0.0" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.606</p_value>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint</title>
        <description>Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Safety Analysis Set: all randomized participants who received study treatment grouped by the treatment actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint</title>
          <description>Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.</description>
          <population>Safety Analysis Set: all randomized participants who received study treatment grouped by the treatment actually taken.</population>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.41" spread="41.43"/>
                    <measurement group_id="O2" value="-5.15" spread="40.32"/>
                    <measurement group_id="O3" value="-4.72" spread="36.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.428</p_value>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Wilcoxin rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint</title>
        <description>Measurement of nanograms of PSA per milliliter (ng/mL) of blood.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Safety Analysis Set: All randomized participants who received study treatment grouped by the treatment actually taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint</title>
          <description>Measurement of nanograms of PSA per milliliter (ng/mL) of blood.</description>
          <population>Safety Analysis Set: All randomized participants who received study treatment grouped by the treatment actually taken.</population>
          <units>Micrograms per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="1.54"/>
                    <measurement group_id="O2" value="0.09" spread="0.88"/>
                    <measurement group_id="O3" value="0.14" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Wilcoxin rank-sum</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Wilcoxin rank-sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint</title>
        <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension period who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint</title>
          <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
          <population>All participants enrolled in the open-label extension period who received at least 1 dose of tadalafil.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="5.9"/>
                    <measurement group_id="O2" value="-5.4" spread="6.3"/>
                    <measurement group_id="O3" value="-6.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint</title>
        <description>IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension period who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint</title>
          <description>IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
          <population>All participants enrolled in the open-label extension period who received at least 1 dose of tadalafil.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.5"/>
                    <measurement group_id="O2" value="-1.6" spread="2.8"/>
                    <measurement group_id="O3" value="-1.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint</title>
        <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label phase who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint</title>
          <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
          <population>All participants enrolled in the open-label phase who received at least 1 dose of tadalafil.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="4.1"/>
                    <measurement group_id="O2" value="-3.7" spread="4.5"/>
                    <measurement group_id="O3" value="-4.3" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint</title>
        <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint</title>
          <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.2"/>
                    <measurement group_id="O2" value="-1.0" spread="1.4"/>
                    <measurement group_id="O3" value="-0.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint</title>
        <description>The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint</title>
          <description>The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.</description>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.0"/>
                    <measurement group_id="O2" value="-1.0" spread="2.4"/>
                    <measurement group_id="O3" value="-0.9" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint</title>
        <description>Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint</title>
          <description>Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).</description>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="4.29"/>
                    <measurement group_id="O2" value="1.51" spread="4.48"/>
                    <measurement group_id="O3" value="2.01" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment</title>
        <description>A listing of Adverse Events are reported in the Reported Adverse Event Section.</description>
        <time_frame>End of 12 weeks of double-blind through 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment</title>
          <description>A listing of Adverse Events are reported in the Reported Adverse Event Section.</description>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure During at 54-Week Endpoint</title>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure During at 54-Week Endpoint</title>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="13.4"/>
                    <measurement group_id="O2" value="-1.2" spread="13.2"/>
                    <measurement group_id="O3" value="-0.5" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="9.6"/>
                    <measurement group_id="O2" value="-2.9" spread="9.2"/>
                    <measurement group_id="O3" value="-1.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Heart Rate at 54-Week Endpoint</title>
        <time_frame>Baseline, 54-weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Heart Rate at 54-Week Endpoint</title>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="10.4"/>
                    <measurement group_id="O2" value="0.4" spread="9.3"/>
                    <measurement group_id="O3" value="2.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint</title>
        <description>Measurement of nanograms of PSA per milliliter (ng/mL) of blood.</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint</title>
          <description>Measurement of nanograms of PSA per milliliter (ng/mL) of blood.</description>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>microgram/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.0"/>
                    <measurement group_id="O2" value="0.3" spread="0.9"/>
                    <measurement group_id="O3" value="0.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint</title>
        <description>Post residual volume (PVR) is measured by ultrasound at regular intervals.</description>
        <time_frame>Baseline, 54 weeks</time_frame>
        <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil 2.5 mg</title>
            <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tadalafil 5 mg</title>
            <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint</title>
          <description>Post residual volume (PVR) is measured by ultrasound at regular intervals.</description>
          <population>All participants enrolled in the open-label extension who received at least 1 dose of tadalafil.</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="50.0"/>
                    <measurement group_id="O2" value="-1.9" spread="42.9"/>
                    <measurement group_id="O3" value="-5.5" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) - defined as events that 1st occurred/worsened after randomization at Week 0.</time_frame>
      <desc>Post-baseline period began after enrollment (Week 12) in open-label extension. If subject reports the occurrence of an event more than once, the most severe of those events was used to determine if event was TE. Analysis of TEAEs was summarized for open-label extension alone (Weeks 12-54). Week 0 of double-blind treatment period was baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil 2.5 mg - Double-Blind Phase</title>
          <description>2.5 milligrams (mg) tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks in the Open-Label Phase.</description>
        </group>
        <group group_id="E2">
          <title>Tadalafil 5 mg - Double-Blind Phase</title>
          <description>5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks during the Open-Label Phase.</description>
        </group>
        <group group_id="E3">
          <title>Placebo - Double-Blind Phase</title>
          <description>Placebo tablet taken by mouth once a day for 12 weeks.
Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks during the Open-Label Phase.</description>
        </group>
        <group group_id="E4">
          <title>Tadalafil 2.5 mg: Tadalafil 5 mg Open-Label</title>
          <description>5 mg tadalafil tablet by mouth once a day for 42 weeks. Participants had previously received 2.5 mg tadalafil in the double-blind phase.</description>
        </group>
        <group group_id="E5">
          <title>Tadalafil 5 mg: Tadalafil 5 mg Open-Label</title>
          <description>5 mg tadalafil tablet by mouth once a day for 42 weeks. Participants had previously received 5 mg tadalafil in the double-blind phase.</description>
        </group>
        <group group_id="E6">
          <title>Placebo: Tadalafil 5 mg Open-Label</title>
          <description>5 mg tadalafil tablet by mouth once a day for 42 weeks. Participants had previously received placebo in the double-blind phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.0">Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 12.0">Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.0">Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.0">Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.0">Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Traumatic arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 12.0">Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="140"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="81" subjects_at_risk="128"/>
                <counts group_id="E6" subjects_affected="94" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E4" events="16" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="142"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="140"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="140"/>
                <counts group_id="E4" events="28" subjects_affected="25" subjects_at_risk="135"/>
                <counts group_id="E5" events="17" subjects_affected="15" subjects_at_risk="128"/>
                <counts group_id="E6" events="31" subjects_affected="19" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tumour marker increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colon polypectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Dental implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tube insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Internal fixation of fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Ureteral catheterisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

